2seventy bio, Inc. (NASDAQ:TSVT) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET

Company Participants

Jenn Snyder - SVP of Corporate Affairs

Nick Leschly - President and Chief Executive Officer

Philip Gregory - Chief Scientific Officer

Steven Bernstein - Chief Medical Officer

William Baird - Chief Financial Officer

Conference Call Participants

Daina Graybosch - Leerink Partners

Yaron Werber - TD Cowen

Kelsey Goodwin - Guggenheim

Vikram Purohit - Morgan Stanley

Daina Graybosch - Leerink Partners

John Newman - Canaccord Genuity

Operator

Good day and thank you for standing by. Welcome to the 2seventy bio Second Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Jenn Snyder, Head of Corporate Affairs. Please go ahead.

Jenn Snyder

Thank you, operator. This afternoon, 2seventy bio issued a press release providing a business update in addition to second quarter 2023 financial results. The press release can be found in the Investors and Media section of the company's website at 270bio.com.

Speaking on the call today are Nick Leschly, Chief Kairos Officer; Chip Baird, Chief Financial Officer; Steve Bernstein, Chief Medical Officer; Philip Gregory, Chief Scientific Officer is also on the line for the Q&A.

As a reminder, today's discussion will include forward-looking statements related to 2seventy bio's current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements include statements regarding our strategic plans, time lines and expectations and statements regarding our financial condition, expectations and other future financial results, among others.

Actual results may differ materially due to various risks, uncertainties and other factors, including those described in the Risk Factors section of our most recent Forms 10-K and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. You are cautioned not to place any undue reliance on these forward-looking statements and except as required by law, we undertake no obligation to update or revise any forward-looking statements.

At this time, I would like to turn the call over to Nick Leschly. Nick?

Nick Leschly

Thanks Jenn. Good afternoon, everyone. Thanks to everyone on the line for joining us as we discuss our second quarter 2023 results and business updates. We are now well into our second full year as 2seventy bio executing on our mission of giving more time to people living with cancer through the transformative power of cell therapy. Since the creation of 270, our mission has always been dual prompt, to deliver on the commercial potential of Abecma and to leverage our translational engine to develop an innovative cell therapy pipeline. And in the first half of 2023, we've made important progress against these goals.